nach oben

Erschienen in:

24.08.2017 | Original Article

New photobiomodulation protocol prevents oral mucositis in hematopoietic stem cell transplantation recipients—a retrospective study

verfasst von: Camila Weissheimer, Marina Curra, Lauro J. Gregianin, Liane E. Daudt, Vivian P. Wagner, Marco Antonio T. Martins, Manoela D. Martins

Erschienen in: Lasers in Medical Science | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Oral mucositis (OM) is an adverse side effect among hematopoietic stem cell transplantation (HSCT) recipients. The objective of this retrospective study was to evaluate the preventive effect of photobiomodulation (PBM) applied three times per week versus seven times per week in patients undergoing HSCT. The risk factors related to the incidence and severity of OM were also assessed. This was a retrospective study that evaluated 99 HSCT recipients who received different PBM protocols. Group I received three sessions per week, and group II received daily treatment. PBM was applied using a continuous-wave diode laser (InGaAlP; MM Optics, São Carlos, SP, Brazil) at a wavelength of 660 nm (visible-red) and a total radiant energy of 0.24 J per point. The baseline disease, type of transplant, type of conditioning, prophylaxis against graft-versus-host disease, OM grade, absolute leukocyte and platelet counts, and levels of liver and renal function markers were collected from medical records. The patients’ age ranged from 13 to 71 years (mean/SD, 40.54 ± 16.45). No significant difference was observed between groups I and II regarding sex, age, ethnic, diagnosis, donor type, and conditioning treatment. Both PBM protocols were equally efficient in preventing OM (p = 0.34, ANOVA). Independent of the PBM protocol used, patients who received allogeneic transplant (p < 0.01—Fischer’s exact test), total body irradiation (TBI-12Gy) (p = 0.01—chi-square test), busulfan + cyclophosphamide (p < 0.01—chi-square test), or methotrexate-containing regimens (p < 0.01—Fischer’s exact test) demonstrated higher OM incidence and severity. Myelosuppression (p < 0.01—Mann-Whitney test) and impaired renal function (p = 0.02—Mann-Whitney test) were also considered risk factors for OM. Based on this retrospective data, PBM was effective in preventing OM in patients undergoing HSCT even when it was applied three times a week. A prospective study might be necessary to confirm these findings.

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J ClinOncol 23(15):3447–3454CrossRef

Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ et al (2014) Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol 166(3):410–420CrossRefPubMed

Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z et al (2014) Association of ABCC2 224C.T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One 9(1):e82681CrossRefPubMedPubMedCentral

Tulsyan S, Agarwal G, Lal P, Mittal B (2014) Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. ClinChimActa 434:21–28

Raber-DurlacherJE ES, Barasch A (2012) Oral mucositis. Oral Oncol 46(6):452–456CrossRef

Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2008) Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer BiolTher 7(7):1139–1145

Ryan AJ, Lin F, Atayee RS (2009) Ketamine mouthwash for mucositis pain. J Palliat Med 12(11):989–991CrossRefPubMed

Vayne-Bossert P, Escher M, de Vautibault CG et al (2010) Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study. J Palliat Med 13(2):125–128CrossRefPubMed

Bezinelli LM, de Paula EF, da Graça Lopes RM et al (2014) Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation. HematolOncol 32(1):31–39

10.

Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed

11.

Sonis ST (2004) Pathobiology of mucositis. Semin Oncol Nurs 20(1):11–15CrossRefPubMed

12.

Keefe DM, Schubert MM, Elting LS et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed

13.

Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral

14.

Martins MA, Martins MD, Lascala CA et al (2012) Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncol 48(1):79–84CrossRefPubMed

15.

Dillenburg CS, Almeida LO, Martins MD, Squarize CH, Castilho RM (2014) Laser phototherapy triggers the production of reactive oxygen species in oral epithelial cells without inducing DNA damage. J Biomed Opt 19(4):048002CrossRefPubMed

16.

Khalighi HR, Mortazavi H, Mojahedi SM, Azari-Marhabi S, Moradi Abbasabadi F (2016) Low level laser therapy versus pharmacotherapy in improving myofascial pain disorder syndrome. J Lasers Med Sci 7(1):45–50CrossRefPubMedPubMedCentral

17.

Pereira AN, Eduardo Cde P, Matson E, Marques MM (2002) Effect of low-power laser irradiation on cell growth and procollagen synthesis of cultured fibroblasts. Lasers Surg Med 31(4):263–267CrossRefPubMed

18.

Wagner VP, Meurer L, Martins MA et al (2013) Influence of different energy densities of laser phototherapy on oral wound healing. J Biomed Opt 18(12):128002CrossRefPubMedPubMedCentral

19.

Pellicioli AC, Martins MD, Dillenburg CS, Marques MM, Squarize CH, Castilho RM (2014) Laser phototherapy accelerates oral keratinocyte migration through the modulation of the mammalian target of rapamycin signaling pathway. J Biomed Opt 19(2):028002CrossRefPubMed

20.

Wagner VP, Curra M, Webber LP et al (2016) Photobiomodulation regulates cytokine release and new blood vessel formation during oral wound healing in rats. Lasers Med Sci 31(4):665–671CrossRefPubMed

21.

Antunes HS, de Azevedo AM, da Silva Bouzas LF et al (2007) Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 109(5):2250–2255CrossRefPubMed

22.

Schubert MM, Eduardo FP, Guthrie KA et al (2007) A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15(10):1145–1154CrossRefPubMed

23.

Eduardo FP, Bezinelli L, Luiz AC, Correa L, Vogel C, Eduardo CP (2009) Severity of oral mucositis in patients undergoing hematopoietic cell transplantation and an oral laser phototherapy protocol: a survey of 30 patients. Photomed Laser Surg 27(1):137–144CrossRefPubMed

24.

Khouri VY, Stracieri AB, Rodrigues MC et al (2009) Use of therapeutic laser for prevention and treatment of oral mucositis. Braz Dent J 20(3):215–220CrossRefPubMed

25.

Chor A, Torres SR, Maiolino A, Nucci M (2010) Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation. Eur J Haematol 84(2):178–179CrossRefPubMed

26.

Lopez TC, Martins MD, Pavesi VC et al (2013) Effect of laser phototherapy in the prevention and treatment of chemo-induced mucositis in hamsters. Braz Oral Res 27(4):342–348CrossRefPubMed

27.

Migliorati C, Hewson I, Lalla RV et al (2013) Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):333–341CrossRefPubMed

28.

Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L (2014) Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 9(9):e107418CrossRefPubMedPubMedCentral

29.

Silva GB, Sacono NT, Othon-Leite AF et al (2015) Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study. Lasers Med Sci 30(1):117–126CrossRefPubMed

30.

Ferreira B, da Motta Silveira FM, de Orange FA (2016) Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support Care Cancer 24(3):1035–1042CrossRefPubMed

31.

Jaguar GC, Prado JD, Nishimoto IN et al (2007) Low-energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantation. Oral Dis 13(6):538–543CrossRefPubMed

32.

Simões A, Eduardo FP, Luiz AC et al (2009) Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers Surg Med 41(4):264–270CrossRefPubMed

33.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457CrossRef

34.

World Health, Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneve, pp 15–22

35.

Blijlevens N, Schwenkglenks M, Bacon P et al (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory group. J ClinOncol 26(9):1519–1525CrossRef

36.

Sonis ST (2011) Oral mucositis. Anti-Cancer Drugs 22(7):607–612CrossRefPubMed

37.

Chaudhry HM, Bruce AJ, Wolf RC et al (2016) The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant 22(4):605–616CrossRefPubMed

38.

Peplow PV, Chung T, Baxter GD (2010) Laser photobiomodulation of wound healing: a review of experimental studies in mouse and rat animal models. Photomed Laser Surg 28(3):291–325CrossRefPubMed

39.

Marques MM, Diniz IM, de Cara SP et al (2016) Photobiomodulation of dental derived mesenchymal stem cells: a systematic review. Photomed Laser Surg 34(11):500–508CrossRefPubMed

40.

Borzabadi-Farahani A (2016) Effect of low-level laser irradiation on proliferation of human dental mesenchymal stem cells; a systemic review. J Photochem Photobiol B 162:577–582CrossRefPubMed

41.

Dillenburg CS, Martins MA, Munerato MC et al (2014) Efficacy of laser phototherapy in comparison to topical clobetasol for the treatment of oral lichen planus: a randomized controlled trial. J Biomed Opt 19(6):068002CrossRefPubMed

42.

Curra M, Pellicioli AC, Filho NA et al (2015) Photobiomodulation reduces oral mucositis by modulating NF-kB. J Biomed Opt 20(12):125008CrossRefPubMed

43.

Campos L, Cruz ÉP, Pereira FS, Arana-Chavez VE, Simões A (2016) Comparative study among three different phototherapy protocols to treat chemotherapy-induced oral mucositis in hamsters. J Biophotonics 9(11–12):1236–1245CrossRefPubMed

44.

Lopez TC, Martins MD, Pavesi VC et al (2013) Effect of laser phototherapy in the prevention and treatment of chemo-induced mucositis in hamsters. Braz Oral Res 27(4):342–348CrossRefPubMed

45.

Stiff P (2001) Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 27(Suppl 2):S3–S11CrossRefPubMed

46.

Vagliano L, Feraut C, Gobetto G et al (2011) Incidence and severity of oral mucostis in patients undergoing haematopoietic SCT—results of a multicentre study. Bone Marrow Transplant 46(5):727–732CrossRefPubMed

47.

Legert KG, Remberger M, Ringdén O, Heimdahl A, Dahllöf G (2014) Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer 22(8):2133–2140CrossRefPubMed

48.

Bolwell BJ, Kalaycio M, Sobecks R et al (2002) A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 30(9):587–591CrossRefPubMed

49.

Shea TC, Bruner R, Wiley JM et al (2003) An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biol Blood Marrow Transplant 9(7):443–452CrossRefPubMed

50.

Rambaldi A, Grassi A, Masciulli A et al (2015) Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 16(15):1525–1536CrossRefPubMed

51.

Cutler C, Li S, Kim HT et al (2005) Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 11(5):383–388CrossRefPubMed

52.

Cheng KK, Lee V, Li CH, Yuen HL, Epstein JB (2012) Oral mucositis in pediatric and adolescent patients undergoing chemotherapy: the impact of symptoms on quality of life. Support Care Cancer 20(10):2335–2342CrossRefPubMed

53.

Suresh AV, Varma PP, Sinha S et al (2010) Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradio-therapy [rssm-hn]. J Cancer Res Ther 6(4):448–451CrossRefPubMed

54.

Mendonça RM, Md A, Levy CE et al (2015) Oral mucositis in pediatric acute lymphoblastic leukemia patients: evaluation of microbiological and hematological factors. Pediatr HematolOncol 32(5):322–330

55.

Carlson K (2005) Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerularfiltration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 35(10):985–990CrossRefPubMed

56.

Grazziutti ML, Dong L, Miceli MH et al (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 38(7):501–506CrossRefPubMed

Titel: New photobiomodulation protocol prevents oral mucositis in hematopoietic stem cell transplantation recipients—a retrospective study
verfasst von: Camila Weissheimer
Marina Curra
Lauro J. Gregianin
Liane E. Daudt
Vivian P. Wagner
Marco Antonio T. Martins
Manoela D. Martins
Publikationsdatum: 24.08.2017
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 9/2017
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-017-2314-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Effects of photobiomodulation on experimental models of peripheral nerve injury

Fast monitoring of tooth erosion caused by medicaments used in the treatment of respiratory diseases by ATR-FTIR and μ-EDXRF analysis

Efficacy of femtosecond lasers for application of acupuncture therapy

Epigenetic changes in preimplantation embryos subjected to laser manipulation.

Leishmanicidal effect of antiparasitic photodynamic therapy—ApPDT on infected macrophages

Low-power laser irradiation inhibits PDGF-BB-induced migration and proliferation via apoptotic cell death in vascular smooth muscle cells